<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of <z:chebi fb="0" ids="50131">decitabine</z:chebi> from its synthesis in 1964 to the submission of a registration file has been described </plain></SENT>
<SENT sid="1" pm="."><plain>Although the unique DNA-demethylating capacity of <z:chebi fb="0" ids="50131">decitabine</z:chebi> is known for a long time, its application is under continuing investigation </plain></SENT>
<SENT sid="2" pm="."><plain>The use of <z:chebi fb="0" ids="50131">decitabine</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mp ids='MP_0005481'>CML</z:mp>, stem cell transplant, sickle cell <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> looks promising </plain></SENT>
<SENT sid="3" pm="."><plain>The epigenetic dose seems lower than the cytotoxic dose </plain></SENT>
<SENT sid="4" pm="."><plain>Whereas most drugs have matured after 40 years, <z:chebi fb="0" ids="50131">decitabine</z:chebi> is only at the beginning of a new development phase in epigenesis </plain></SENT>
</text></document>